Chenxiang Tang
Chief Executive Officer Circode Biomed
Dr. Chenxiang Tang graduated from Tsinghua University with dual degrees in Life Sciences and Economics, and earned his Ph.D. in Molecular Biophysics and Biochemistry from Yale University in the United States. He has over ten years of experience in biomedical research and development, industrialization, and management, with extensive experience in corporate operations management. Dr. Tang has held positions such as Assistant to the Chairman of SOHO China, Assistant to the President of Shanghai Mab-Venture, and CEO of Hengrui Medicine’s subsidiary, MabGen Biotech.
Seminars
Advancing novel RNA therapeutics requires early, aligned decisions that strengthen manufacturability and regulatory readiness. This workshop provides a practical framework for designing circular and self-amplifying RNA constructs, anticipating CMC risks and building streamlined development paths that reduce rework and accelerate IND timelines.
This workshop will gather experts to discuss:
- Accelerate IND timelines by applying structured design principles that cut construct development cycles and improve potency/durability.
- Prevent scale-up failures by identifying manufacturability and CMC risks early, ensuring GMP consistency and reducing costly rework.
- Minimize IND deficiencies by aligning regulatory expectations with analytical and CMC strategies, reducing late-stage surprises.
- Unify design, manufacturing, and regulatory teams to enable faster decision-making and reduce development bottlenecks.
This workshop is for:
R&D leaders, CMC teams, program directors, regulatory strategists and platform developers seeking a more predictable and accelerated path from sequence design to IND
- Validate circular RNA as a clinically viable therapeutic modality by sharing global first-in-human dosing experience and early clinical insights from ischemic disease programs
- De-risk indication and modality selection by translating preclinical durability, expression, and safety data into real-world clinical decision-making frameworks
- Inform next-generation RNA development strategies by extracting early lessons on dosing, delivery, and trial design from one of the field’s first clinical programs
